Another factor in Vertex’s stock rising this week relates to its collaborations with Moderna, including partnerships to discover and develop mRNA therapies for cystic fibrosis (CF), as well as to discover and develop inhalable lipid nanoparticles (LNPs) to deliver those therapies. Moderna is partnering with Vertex on two parallel approaches for addressing the unmet need to deliver CF treatments to the approximately 5,000 CF patients who do not produce any CFTR protein . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge